SRR1320560
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.549
- HYPOXIA+0.343
- P53_PATHWAY+0.325
- COAGULATION+0.313
- MYOGENESIS+0.277
- XENOBIOTIC_METABOLISM+0.271
- ADIPOGENESIS+0.263
- ESTROGEN_RESPONSE_LATE+0.259
- ESTROGEN_RESPONSE_EARLY+0.239
- SPERMATOGENESIS+0.234
Top 10 suppressed
- E2F_TARGETS-0.413
- G2M_CHECKPOINT-0.384
- NOTCH_SIGNALING-0.348
- DNA_REPAIR-0.313
- PROTEIN_SECRETION-0.295
- MYC_TARGETS_V2-0.245
- MITOTIC_SPINDLE-0.241
- MYC_TARGETS_V1-0.240
- ALLOGRAFT_REJECTION-0.188
- TGF_BETA_SIGNALING-0.106
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1399051 | GTEX | — | 0.873 |
| 2 | SRR817927 | GTEX | — | 0.863 |
| 3 | SRR662978 | GTEX | — | 0.858 |
| 4 | SRR1328487 | GTEX | — | 0.849 |
| 5 | SJEPD021_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.819 |
| 6 | SRR1471922 | GTEX | — | 0.807 |
| 7 | SRR1471903 | GTEX | — | 0.800 |
| 8 | SRR1472394 | GTEX | — | 0.793 |
| 9 | SRR817978 | GTEX | — | 0.787 |
| 10 | SRR818971 | GTEX | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.549 | Inavolisib | — uncovered |
| HYPOXIA | 0.343 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.325 | Idelalisib | — uncovered |
| COAGULATION | 0.313 | Binimetinib | — uncovered |
| MYOGENESIS | 0.277 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.271 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.263 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.259 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.239 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.234 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.216 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.215 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.206 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.203 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.196 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.192 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.171 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.167 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.163 | Inavolisib | — uncovered |